Earnings summaries and quarterly performance for Wave Life Sciences.
Executive leadership at Wave Life Sciences.
Board of directors at Wave Life Sciences.
Research analysts who have asked questions during Wave Life Sciences earnings calls.
Catherine Novack
JonesTrading Institutional Services LLC
4 questions for WVE
Also covers: ALDX, CAPR, CRNX +3 more
JL
Joon Lee
Truist Securities
4 questions for WVE
Also covers: ADVM, AXSM, CNM +14 more
MW
Madison Wynne El-Saadi
B. Riley Securities
4 questions for WVE
Also covers: AGEN, CAPR, ETON +1 more
SS
Salim Syed
Mizuho Securities
4 questions for WVE
Also covers: AUTL, BBIO, CYTK +5 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for WVE
Also covers: ACRS, CRVS, CTMX +12 more
JS
Joseph Schwartz
Oppenheimer
2 questions for WVE
Also covers: ASND, AUPH, BMRN +14 more
LW
Lisa Walter
RBC Capital Markets
2 questions for WVE
Also covers: APLS, EYPT, OCUL +2 more
RF
Ron Feiner
Leerink Partners
2 questions for WVE
Also covers: KYMR
Ananda Ghosh
H.C. Wainwright & Co.
1 question for WVE
Also covers: ABOS, ALEC, AMLX +1 more
AF
Andrew Fein
H.C. Wainwright & Co.
1 question for WVE
Anthony
Raymond James
1 question for WVE
Also covers: AB, COO, TRVI
Cheng Li
Oppenheimer & Co. Inc.
1 question for WVE
Also covers: EDIT, EXEL, INO +3 more
Eric Joseph
JPMorgan Chase & Co.
1 question for WVE
Also covers: BEAM, BLUE, ENTA +9 more
Jenny Leigh Gonzalez-Armenta
Leerink Partners
1 question for WVE
Also covers: QURE
JS
Joe Schwartz
Leerink Partners
1 question for WVE
Also covers: BMRN, KALV, PTGX
LI
Luca Issi
RBC Capital Markets
1 question for WVE
Also covers: ADVM, ALLO, ALNY +12 more
Martin Auster
Raymond James
1 question for WVE
NE
Nicholas Econom
Raymond James
1 question for WVE
Also covers: APLS, EDIT
RS
Roger Song
Jefferies
1 question for WVE
Also covers: AADI, AKBA, ALT +13 more
Ryan Deschner
Raymond James Financial
1 question for WVE
Also covers: APLS, ARDX, ARSP +7 more
Samantha Semenkow
Citigroup Inc.
1 question for WVE
Also covers: ALLO, ARGX, BEAM +7 more
SS
Steven Seedhouse
Raymond James
1 question for WVE
Also covers: APLS, BCRX, EDIT +2 more
Steve Seedhouse
Cantor Fitzgerald
1 question for WVE
Also covers: BCRX, BOLD, HROW +1 more
TF
Tiago Fauth
Wells Fargo
1 question for WVE
Also covers: LQDA, PTCT, VRNA
YJ
Yun Jung
Wedbush Securities
1 question for WVE
Yun Zhong
Wedbush Securities
1 question for WVE
Also covers: ASND, MNKD, MRKR +2 more
Recent press releases and 8-K filings for WVE.
Wave Life Sciences Ltd. Announces Upsized Public Offering and Cash Runway Update
WVE
Guidance Update
New Projects/Investments
- Wave Life Sciences Ltd. priced an upsized public offering of 15,789,475 ordinary shares at $19.00 per share and 2,631,578 pre-funded warrants at $18.9999 per pre-funded warrant.
- The underwriters fully exercised their option to purchase an additional 2,763,157 ordinary shares on December 10, 2025.
- Gross proceeds from the offering are expected to be approximately $402.5 million, including the full exercise of the underwriters' option.
- The offering is expected to close on or about December 11, 2025.
- Following the closing, the company expects to have approximately 187,693,059 ordinary shares outstanding and its current cash and cash equivalents will be sufficient to fund operations into the third quarter of 2028.
Dec 11, 2025, 2:47 AM
Wave Life Sciences Prices Public Offering
WVE
- Wave Life Sciences announced the pricing of an underwritten public offering of ordinary shares and pre-funded warrants on December 9, 2025.
- The offering includes 15,789,475 ordinary shares at $19.00 per share and 2,631,578 pre-funded warrants at $18.9999 per warrant.
- The company expects to receive approximately $350 million in gross proceeds from the offering.
- The offering is anticipated to close on or about December 11, 2025.
Dec 10, 2025, 2:50 AM
Wave Life Sciences Announces Proposed Public Offering
WVE
- Wave Life Sciences (Nasdaq: WVE) has commenced an underwritten public offering to raise $250 million in aggregate through the sale of its ordinary shares and pre-funded warrants.
- The company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the total amount of ordinary shares and shares underlying pre-funded warrants sold.
- Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering.
- The offering is subject to market and other conditions, with no assurance as to its completion, actual size, or terms.
Dec 8, 2025, 9:01 PM
Wave Life Sciences Reports Positive Interim Clinical Data for WVE-007 in Obesity
WVE
New Projects/Investments
- Wave Life Sciences announced positive interim clinical data from its Phase 1 INLIGHT trial of WVE-007 for obesity.
- A single 240 mg dose of WVE-007 led to improved body composition at three months, including a 4.5% reduction in total body fat and a 9.4% reduction in visceral fat, while preserving muscle mass with a 3.2% increase in lean mass.
- The treatment was generally safe and well tolerated through 600 mg, with no serious adverse events or discontinuations reported.
- The company is planning Phase 2 trials for WVE-007 across multiple treatment settings, including monotherapy and as an add-on to incretin treatments.
- Further data updates are anticipated in 1Q26, including 6-month follow-up from the 240 mg cohort and 3-month follow-up from the 400 mg cohort.
Dec 8, 2025, 1:30 PM
Wave Life Sciences Announces Positive Interim Clinical Data for WVE-007
WVE
New Projects/Investments
- Wave Life Sciences reported positive interim clinical data from its ongoing Phase 1 IN-LIGHT trial of WVE-007, an inhibin E GalNAc siRNA, in individuals living with overweight or obesity.
- After three months, a single dose of WVE-007 (240mg cohort) led to a 4.5% reduction in total body fat, a 9.4% reduction in visceral fat, and a 3.2% increase in lean mass. These improvements in body composition were observed in participants without diet or exercise modifications.
- The trial demonstrated a favorable safety profile for WVE-007, with no discontinuations, serious treatment-emergent adverse events (TEAEs), or deaths through the 600mg cohort, and all drug-related AEs were mild.
- WVE-007 achieved total fat reductions comparable to semaglutide at 12 weeks, while preserving lean mass and driving greater reductions in visceral fat, supporting a convenient once or twice yearly dosing interval.
- The company anticipates releasing six-month follow-up data from the 240mg cohort and three-month data from the 400mg cohort in the next quarter, with further data from higher doses and longer durations expected in Q2 2026.
Dec 8, 2025, 1:30 PM
Wave Life Sciences Announces Positive Interim Clinical Data for WVE-007
WVE
Product Launch
New Projects/Investments
- Wave Life Sciences announced positive interim clinical data from its Phase 1 IN-LIGHT trial of WVE-007 for individuals living with overweight or obesity.
- After a single 240-mg dose over three months, participants demonstrated a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass. These results were observed in healthier participants without diet or exercise modifications.
- The data showed robust and durable suppression of Activin E, supporting a convenient once or twice per year dosing schedule, coupled with a favorable safety profile.
- WVE-007's fat loss was comparable to semaglutide at three months, while notably preserving lean mass and achieving greater visceral fat reduction.
- Upcoming milestones include six-month follow-up data for the 240-mg cohort and three-month data for the 400-mg cohort next quarter, with further data expected in Q2 2026.
Dec 8, 2025, 1:30 PM
Wave Life Sciences Announces Positive Interim Clinical Data for WVE-007 in Obesity Trial
WVE
New Projects/Investments
- Wave Life Sciences announced positive interim clinical data from its Phase I INLIGHT trial of WVE-007, an INHBE GalNAc-siRNA for individuals living with overweight or obesity, on December 8, 2025.
- A single 240-mg dose of WVE-007 demonstrated significant body composition improvements at three months, including a 9.4% reduction in visceral fat, a 4.5% reduction in total body fat, and a 3.2% increase in lean mass.
- The treatment achieved fat loss comparable to GLP-1s while preserving muscle, and exhibited a favorable safety profile supporting once or twice per year dosing.
- The company anticipates releasing six-month follow-up data for the 240-mg cohort and three-month data for the 400-mg cohort in Q1 2026, with additional data expected in Q2 2026.
Dec 8, 2025, 1:30 PM
Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity
WVE
New Projects/Investments
- Wave Life Sciences announced positive interim data from the Phase 1 INLIGHT trial evaluating WVE-007 for the treatment of obesity.
- A single 240 mg dose of WVE-007 resulted in a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (p=0.07), and a 3.2% increase in lean mass (p=0.01) at three months, with no statistically significant changes in the placebo group.
- WVE-007 was generally safe and well-tolerated, with only mild treatment-related adverse events and no clinically meaningful changes in clinical laboratory measurements, supporting potential once or twice-yearly dosing.
- The company is planning for Phase 2 trials and anticipates further clinical data updates in Q1 2026 and Q2 2026.
Dec 8, 2025, 12:37 PM
Wave Life Sciences to Announce Interim Data for WVE-007 Clinical Trial
WVE
New Projects/Investments
- Wave Life Sciences (Nasdaq: WVE) will announce interim data from its Phase 1 INLIGHT clinical trial evaluating WVE-007 on Monday, December 8, 2025.
- WVE-007 is an investigational GalNAc-siRNA designed to treat obesity by silencing INHBE mRNA, a target supported by strong human genetics evidence.
- Preclinical studies showed that WVE-007 led to metabolic improvements, including adipocyte shrinkage and improved insulin sensitivity, and doubled weight loss in mice when combined with semaglutide.
- The INLIGHT trial is a first-in-human study assessing the safety, tolerability, pharmacokinetics, and various metabolic health biomarkers of WVE-007 in adults with overweight or obesity.
Dec 7, 2025, 9:00 PM
Wave Life Sciences discusses pipeline progress and upcoming data readouts at Jefferies Healthcare London Conference 2025
WVE
New Projects/Investments
- Wave Life Sciences is advancing its RNA medicines pipeline, with key programs in RNA editing and siRNA, and anticipates a data-rich period in Q4 2025 and 2026.
- The WVE-007 (inhibin E) program for obesity demonstrated dose-dependent reductions in activin E levels in clinical data, with a 75% reduction at 240 mg and an 85% reduction at 400 mg.
- Upcoming catalysts for WVE-007 include three-month data on the 240 mg cohort in Q4 2025 and six-month data on the 240 mg cohort and three-month data on the 400 mg cohort in Q1 2026, focusing on fat loss and body composition.
- The WVE-006 RNA editing program for alpha-1 antitrypsin deficiency (AATD) showed potent and durable editing, correcting patients to the MZ phenotype with over 20 micromolar of total protein and nearly 11 micromolar of M protein at the lowest single dose.
- Wave plans to initiate clinical trials for WVE-008 (PNPLA3), an RNA editing program for liver disease, in 2026, targeting a large patient population.
Nov 20, 2025, 9:00 AM
Quarterly earnings call transcripts for Wave Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more